washington  reuters    democrats on a powerful u s  congressional panel are questioning whether canada based valeant pharmaceuticals may be wrongfully withholding documents in connection with its ongoing probe into sky rocketing drug prices  according to an internal memo seen by reuters on tuesday  the memo  which was sent to democratic members of the house of representatives committee on oversight and government reform from the staff of its top democrat elijah cummings  reveals that valeant previously withheld readily available analyst reports prepared by banks such as goldman sachs  saying they were protected by attorney client privilege  the memo says it also raises questions about other documents that are still being withheld  saying some of these  were not drafted by attorneys and do not include communications with attorneys   a spokeswoman for valeant denied that the company has done anything wrong  saying it has already provided more than   pages of documents and will continue cooperating   we continue to discuss with the committee the issue of privileged documents  but any suggestion that we have withheld documents inappropriately is incorrect   laurie little said in a statement  the april  memo comes just one day before three of valeant s top executives are slated to appear before a different u s  senate panel that is also investigating high drug prices  the company s outgoing ceo michael pearson will be testifying before the senate special committee on aging late wednesday afternoon  along with activist investor william ackman  a majority shareholder and board member  and howard schiller  a director and former chief financial officer  their appearance before congress comes at an awkward and difficult time for the company  which is under fire from its shareholders and facing a number of ongoing government investigations into drug pricing and distribution  accounting and disclosures  and antitrust matters  last month  the company announced that pearson would be stepping down and that ackman would be joining its board  after a board committee probe into the company s dealings with specialty pharmacy philidor rx services uncovered accounting problems dating back to december   the company said it would restate its earnings and delay filing its annual report  opening the door to a possible default on its   billion debt  the company has blamed some of the accounting problems on schiller  and asked him to step down from his board seat  schiller has refused to do so  and has denied any wrongdoing through his attorney  valeant plans to file its annual report on april   two days after the hearing  wednesday s hearing will be primarily focused on valeant s drastic price increases for two of its heart drugs  the committee previously planned to vote to hold pearson in contempt for failing to be deposed  but backed down after he agreed to be interviewed april   